Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study

Combination therapy with inhibitors of cytotoxic T lymphocyte-associated protein (CTLA)4 and programmed death (PD)-1 has demonstrated efficacy in cancer patients. However, there is little information on CTLA4 and PD-1 expression levels and their clinical significance across diverse cancers. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jian-Nan, Kong, Xiang-Shuo, Huang, Tao, Wang, Rui, Li, Wang, Chen, Qi-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539667/
https://www.ncbi.nlm.nih.gov/pubmed/33072070
http://dx.doi.org/10.3389/fimmu.2020.02048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539667/
https://www.ncbi.nlm.nih.gov/pubmed/33072070
http://dx.doi.org/10.3389/fimmu.2020.02048

Ejemplares similares